ArticleEuropean journal of histochemistry : EJH2025
Solamargine inhibited the progression of non-small cell lung cancer
Article in European journal of histochemistry : EJH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer-related death globally and the most common cancer type. Solamargine is an extract from the traditional Chinese medicine, Long Kui, which exhibits antitumor effects in a number of cancer types, including lung cancer. However, the possible association between solamargine and the tumor microenvironment (TME) in non-small cell lung cancer (NSCLC) remains to be elucidated. In the present study, Cell Counting Kit-8 and 5-Ethynyl-2'-deoxyuridine (EdU) assays were used to evaluate the viability and proliferation of NSCLC cells, respectively. In addition, NSCLC cells were co-cultured with peripheral blood mononuclear cells with or without prior solamargine treatment to evaluate the possible association between solamargine and the TME. The results indicated that solamargine can inhibit NSCLC cell proliferation and migration directly. In addition, it was demonstrated that solamargine can prevent the progression of NSCLC indirectly via activating the function of T cells. These findings may provide a novel theoretical basis in drug discovery for the treatment of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.